Summary
AXSM Chart
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June:
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Hetero a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
Axsome Therapeutics Inc. Dividends
Axsome Therapeutics Inc. Earnings
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 5 Aug 2024 Date | | - Cons. EPS | - EPS |
| 5 May 2025 Date | | - Cons. EPS | - EPS |
| 18 Feb 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 4 Nov 2024 Date | | - Cons. EPS | - EPS |
| 5 Aug 2024 Date | | - Cons. EPS | - EPS |
Axsome Therapeutics Inc. (AXSM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Axsome Therapeutics Inc. ever had a stock split?
Axsome Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Herriot Tabuteau M.D. CEO | NASDAQ (NMS) Exchange | 05464T104 Cusip |
| US Country | 712 Employees | - Last Dividend | - Last Split | 19 Nov 2015 IPO Date |
Overview
Axsome Therapeutics, Inc. is a forward-thinking biopharmaceutical entity dedicated to the innovation of novel treatments geared towards addressing the complexities of central nervous system (CNS) disorders. Rooted in the quest to improve patient care within the United States, Axsome stands out for its dynamic approach towards tackling conditions such as major depressive disorder, narcolepsy, obstructive sleep apnea, Alzheimer's disease agitation, and more. The foundation of the company's operations, established in 2012 and headquartered in New York, New York, underscores a commitment to pushing the boundaries of medical science, particularly in the CNS domain. Through its research collaboration with Duke University focused on smoking cessation, Axsome exemplifies its dedication to pioneering efforts in enhancing therapeutic outcomes.
Products and Services
- Auvelity (dextromethorphan-bupropion): An innovative N-methyl-D-aspartate receptor antagonist showcasing multimodal activity, specifically indicated for the treatment of major depressive disorder, highlighting Axsome's focus on addressing mental health challenges with novel approaches.
- Sunosi (solriamfetol): A targeted medication addressing excessive daytime sleepiness in patients battling narcolepsy or obstructive sleep apnea, underlining the company's dedication to improving quality of life for individuals with sleep disorders.
Under Development:
- AXS-05: Currently in Phase III clinical trial for Alzheimer's disease agitation, showcasing Axsome's deep dive into neurodegenerative disease management. Additionally, it demonstrates versatility with its completion of Phase II clinical trial for smoking cessation.
- AXS-07: An investigational medicine that has successfully completed Phase III trials, crafted for the acute treatment of migraine, providing a glimpse into Axsome's commitment to tackling severe headache disorders.
- AXS-12: In Phase III trial to treat narcolepsy, positioning Axsome at the forefront of addressing sleep disorders with cutting-edge solutions.
- AXS-14: Having completed Phase III trial for the treatment of fibromyalgia, this selective and potent norepinephrine reuptake inhibitor represents Axsome's venture into pain management and other potential conditions.
- Solriamfetol: Beyond its approved use, it is under investigation in a Phase 2 trial for addressing attention-deficit/hyperactivity disorder. Additionally, its exploration extends to major depressive, binge eating, and shift work disorders, showing Axsome's holistic approach to CNS conditions.
Contact Information
